8 results about "Oxybutynine" patented technology

The invention relates to a preparation method of oxybutynin, and particularly provides a preparation method of a condensing agent di (2-pyrimidinyl) carbonate and oxybutynin. According to the preparation method, 2-cyclohexyl-2-hydroxyphenylacetic acid and 4, 4-diethylamino-2-butyne-1-alcohol are used as raw materials, di (2-pyrimidinyl) carbonate is used as a condensing agent, condensation reaction is performed to prepare oxybutynin, the reaction yield and the product purity can be remarkably improved, and the reaction conditions are milder.

In general, the invention relates to pharmaceutical compositions comprising (R)-oxybutynin and a norepinephrine reuptake inhibitor (NRI) and methods of treating Sleep Apnea comprising administering (R)-oxybutynin and a norepinephrine reuptake inhibitor (NRI). In some embodiments, the NRI is atomoxetine.

A composition for treating peripheral neuropathy in a subject in need thereof. The composition comprises an effective amount of an agent selected from the group consisting of pirenzepine, oxybutynin, muscarinic toxin 7, muscarinic receptor antagonists, and combinations thereof, and a pharmaceutically acceptable carrier and / or excipient. The composition is used for treating peripheral neuropathy. Examples of the peripheral neuropathy are systemic disease-induced peripheral neuropathy, metabolic disease-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, compression-induced peripheral neuropathy, dichloroacetate-contact-induced peripheral neuropathy, immune-mediated peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy, chemotherapy-induced peripheral neuropathy and chemotherapy-induced peripheral neuropathy. And infection-induced peripheral neuropathy and gene-obtained peripheral neuropathy.

The present invention discloses a method for resolving cyclohexylphenyl glycolic acid and the preparation of optically active phenylcyclohexyl glycolate esters. More particularly, the invention provides a process for preparation of optically active R-oxybutynin hydrochloride with high enantiomeric purity of greater than 99%.

Polymorphic forms of (R)-oxybutynin HCl, including three crystalline forms, are prepared and characterized. Uses of the various polymorphic forms of (R)-oxybutynin HCl for Obstructive Sleep Apnea (OSA) treatment are also disclosed.

The present disclosure provides a solution composition comprising about 0.5% w / v to about 30% w / v of atomoxetine and about 0.1% w / v to about 20% w / v of oxybutynin, a penetration enhancer, at least 40% w / v of an aliphatic solvent, and a film forming excipient, wherein the composition forms a washable and / or a peelable film when sprayed on a skin surface, and wherein the atomoxetine and oxybutynin do not crystallize before dermal absorption when the composition is applied to the skin surface. The disclosure also provides a method of treating obstructive sleep apnea in a subject in need thereof, the method comprising topically administering to the subject the topical compositions as described herein.

The present disclosure provides a solution composition comprising about 0.5% w / v to about 30% w / v of atomoxetine and about 0.1% w / v to about 20% w / v of oxybutynin, a penetration enhancer, at least 40% w / v of an aliphatic solvent, and a film forming excipient, wherein the composition forms a washable and / or a peelable film when sprayed on a skin surface, and wherein the atomoxetine and oxybutynin do not crystallize before dermal absorption when the composition is applied to the skin surface. The disclosure also provides a method of treating obstructive sleep apnea in a subject in need thereof, the method comprising topically administering to the subject the topical compositions as described herein.

Methods for treating obstructive sleep apnea using GLP-1 receptor agonists and second activators, as well as related pharmaceutical compositions and therapeutic combinations, are described herein. The second activator is selected from the group consisting of atomoxetine, reboxetine, biloxazine, ediboxetine, oxybutinin, and trazodone, and their stereoisomers and pharmaceutically acceptable salts.